Multifocal radiculoneuropathy during ipilimumab treatment of melanoma
- 27 July 2013
- journal article
- case report
- Published by Wiley in Muscle & Nerve
- Vol. 48 (3), 440-444
- https://doi.org/10.1002/mus.23830
Abstract
Introduction: Ipilimumab, a monoclonal anti–CTLA‐4 antibody, is used to treat melanoma. Neuromuscular side effects, possibly autoimmune, may occur. Methods: In this investigation we undertook a retrospective review of patient records. Results: After 3 doses of ipilimumab, a 31‐year‐old man developed asymmetric, severe weakness involving all limbs, respiration, and cranial nerves, which was progressive over 2 weeks. EMG/NCS showed an axonal polyradiculoneuropathy with multifocal motor conduction blocks. CSF protein was 749 mg/dl. Nerve pathology showed inflammation around the endoneurial microvessels and subperineurial edema and inflammation. Spine MRI showed leptomeningeal and anterior and posterior root enhancement. Strength improved slowly over months after ipilimumab discontinuation and immunomodulating treatment. Conclusions: Ipilimumab toxicity presented as a monophasic, multifocal, asymmetric polyradiculoneuropathy involving roots and peripheral and cranial nerves. Ipilimumab may produce a polyradiculoneuropathy with disruption of the blood–nerve barrier due to a microvasculopathy. Muscle Nerve 48: 440–444, 2013Keywords
This publication has 23 references indexed in Scilit:
- Severe meningo-radiculo-nevritis associated with ipilimumabInvestigational New Drugs, 2012
- Vasculitic Neuropathy Associated With Minocycline UseJournal of Clinical Neuromuscular Disease, 2011
- Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patientAnnals Of Oncology, 2011
- Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other TumorsCancer Biotherapy & Radiopharmaceuticals, 2010
- Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non‐systemic vasculitic neuropathy: executive summaryJournal of the Peripheral Nervous System, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- CTLA4 blockade increases Th17 cells in patients with metastatic melanomaJournal of Translational Medicine, 2009
- Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for MelanomaJournal of Immunotherapy, 2009
- Cranial Neuropathy as a Presenting Sign of Recurrent Aggressive Skin CancerDermatologic Surgery, 2008
- Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic MelanomaJournal of Immunotherapy, 2004